Skip to main content
. 2012 May 3;1(2):103–111. doi: 10.1093/jpids/pis044

Table 1.

Demographic and Characteristics for 198 Enrolled Patients

Characteristic No. (%)
Sex
 Male 121 (61)
 Female 77 (39)
Race
 Caucasian 161 (82)
 African American 15 (8)
 Othera 21 (10)
Ethnicity
 Hispanic 19 (10)
 Non-Hispanic 177 (89)
 Unknown 2 (1)
Age, Median (IQR) 7.8 (3.7–13.5)
HSCT, with underlying diagnosis
 Total 169 (85)
 HSCT for ALL 36 (18)
 HSCT for AML/MDS 39 (20)
 HSCT for solid tumor 30 (15)
 HSCT, otherb 64 (32)
Chemotherapy, with underlying diagnosis
 Total 29 (15)
 ALL 6 (3)
 AML/MDS 17 (9)
 Solid tumor 6 (3)
Duration neutropeniac
 Mean 24.8
 Median 20
 Range 3–343
Antifungal prophylaxisc
 Any prophylaxis 185
 Fluconazole 143 (77)
 Voriconazole 15 (8)
 Caspofungin 7 (4)
 Amphotericin product 20 (11)
Chemotherapy contained steroid exposured 65 (37)
TBI exposuree 83 (47)

Abbreviations: ALL, acute lymphoblastic leukemia; AML/MDS, acute myeloid leukemia/ myelodysplastic syndrome; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; TBI, traumatic brain injury.

aIncludes Asian (n = 4), Native American (n = 6), Pacific Islander (n = 2), other (n = 7), and unknown (n = 2).

bThe most common other diagnoses included severe aplastic anemia (n = 11), chronic myelogenous leukemia (n = 7), Hodgkin's lymphoma (n = 7), Wiskott-Aldrich syndrome (n = 4), Fanconi anemia (n = 4).

cData available for 185 of the 198 enrolled patients.

dData available for 178 of the 198 enrolled patients.

eData available for 176 of the 198 enrolled patients.